Compare CCO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | EYPT |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2005 | 2005 |
| Metric | CCO | EYPT |
|---|---|---|
| Price | $2.33 | $14.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $2.12 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 7.3M | 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $7,539,000.00 |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $4.26 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.57 | N/A |
| 52 Week Low | $1.16 | $9.65 |
| 52 Week High | $2.44 | $19.11 |
| Indicator | CCO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 32.05 | 59.30 |
| Support Level | $2.33 | $11.86 |
| Resistance Level | $2.41 | $15.01 |
| Average True Range (ATR) | 0.03 | 0.88 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 25.00 | 97.48 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.